Nrx Pharmaceuticals, Inc. NRXP
We take great care to ensure that the data presented and summarized in this overview for NRX Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NRXP
Top Purchases
Top Sells
About NRXP
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Insider Transactions at NRXP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2024
|
Jonathan C Javitt Chairman and Chief Scientist |
BUY
Open market or private purchase
|
Direct |
40,000
+32.09%
|
$40,000
$1.17 P/Share
|
|
Aug 30
2023
|
Aaron Gorovitz |
BUY
Open market or private purchase
|
Indirect |
35,000
+25.0%
|
$0
$0.32 P/Share
|
|
Aug 30
2023
|
Chaim Hurvitz |
BUY
Open market or private purchase
|
Direct |
70,000
+10.94%
|
$0
$0.29 P/Share
|
|
Aug 23
2023
|
Jonathan C Javitt Chairman and Chief Scientist |
BUY
Open market or private purchase
|
Direct |
100,000
+18.3%
|
$0
$0.33 P/Share
|
|
Aug 22
2023
|
Jonathan C Javitt Chairman and Chief Scientist |
BUY
Open market or private purchase
|
Direct |
200,000
+36.61%
|
$0
$0.32 P/Share
|
|
Dec 16
2022
|
Seth Van Voorhees CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
30,000
+39.3%
|
$30,000
$1.1 P/Share
|
|
Dec 16
2022
|
Stephen H Willard CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
50,000
+50.0%
|
$50,000
$1.17 P/Share
|
|
Dec 07
2022
|
Jonathan C Javitt Chairman and Chief Scientist |
SELL
Open market or private sale
|
Indirect |
400,000
-3.01%
|
$400,000
$1.0 P/Share
|
|
Nov 30
2022
|
Daniel C. Javitt > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,441
-0.09%
|
$8,441
$1.5 P/Share
|
|
Nov 29
2022
|
Daniel C. Javitt > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,730
-0.14%
|
$13,730
$1.5 P/Share
|
|
Nov 28
2022
|
Patrick John Flynn |
BUY
Open market or private purchase
|
Direct |
1,750
+50.0%
|
$1,750
$1.25 P/Share
|
|
Nov 28
2022
|
Patrick John Flynn |
BUY
Open market or private purchase
|
Indirect |
10,000
+6.04%
|
$10,000
$1.25 P/Share
|
|
Nov 25
2022
|
Seth Van Voorhees CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Indirect |
16,337
+28.69%
|
$16,337
$1.11 P/Share
|
|
Nov 18
2022
|
Chaim Hurvitz |
BUY
Open market or private purchase
|
Direct |
40,408
+7.48%
|
$40,408
$1.1 P/Share
|
|
Nov 17
2022
|
Chaim Hurvitz |
BUY
Open market or private purchase
|
Direct |
171,780
+27.21%
|
$171,780
$1.08 P/Share
|
|
Nov 17
2022
|
Daniel C. Javitt > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
33,018
-0.34%
|
$33,018
$1.05 P/Share
|
|
Nov 16
2022
|
Chaim Hurvitz |
BUY
Open market or private purchase
|
Direct |
287,812
+50.0%
|
$0
$0.99 P/Share
|
|
Nov 16
2022
|
Daniel C. Javitt > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
133,719
-1.36%
|
$133,719
$1.02 P/Share
|
|
Nov 11
2022
|
Daniel C. Javitt > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
49,200
-0.5%
|
$49,200
$1.01 P/Share
|
|
Jul 29
2022
|
Daniel C. Javitt > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
784,063
-7.36%
|
$784,063
$1.01 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 40K shares |
|---|